Answers are grounded in this paper and cite their sources.
Chronic stress may influence vulnerability to persistent pain, the transition from acute to chronic pain, and symptom maintenance through interacting neuroendocrine, neuroimmune, neuronal, and behavioral pathways. This narrative review synthesizes evidence on hypothalamic–pituitary–adrenal axis and glucocorticoid regulation, inflammatory activation and resolution, glial-neuronal signaling, descending pain modulation, and emerging transcriptomic and epigenetic mechanisms. We distinguish findings directly demonstrated in stress-exposure models from mechanisms established in neuropathic or inflammatory pain and from largely associative human molecular observations. Experimental studies implicate pathways including FKBP5/FKBP51, microglial P2X4-p38 MAPK-BDNF-TrkB-KCC2 signaling, inflammasomes, and periaqueductal gray-rostral ventromedial medulla circuits; however, causal roles vary by model, stressor, disease stage, and pain phenotype. We also examine how sleep disruption, distress, physical activity, and fear-avoidance interact with pain processing. A stage-dependent, phenotype-sensitive synthesis differentiates susceptibility, chronification, and maintenance and distinguishes central sensitization from nociplastic pain. Established multimodal management should be guided by diagnosis, functional goals, and modifiable clinical factors rather than unvalidated endocrine or omics markers. Prospective stress-characterized cohorts, causal pathway testing, and biomarker-by-treatment trials are needed to determine whether molecular findings can improve prevention and individualized care.
No takes yet. Share an insight, caveat, or question.
Gajic et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: